CVS Health stock moves and recent performance

With no single headline event driving CVS Health (CVS) today, the stock's recent performance and business profile give you most of the context for thinking about its role in a diversified portfolio.

The recent 1-day share price return of 1.47% and 7-day return of 6.29% build on a 90-day share price return of 34.44%, while the 1-year total shareholder return of 56.67% points to momentum that has been strong over both shorter and longer horizons.

If this kind of move has you thinking about what else is gaining traction, it could be worth scanning 40 healthcare AI stocks as a starting point for other potential ideas.

With the stock around US$101.96, trading only about 2% below one set of analyst targets yet flagged by some models as having a large intrinsic discount, the key question is whether CVS Health is still mispriced or whether the market is already accounting for future growth.

Most Popular Narrative: 2% Undervalued

Compared with the last close at $101.96, the most followed narrative sees fair value for CVS Health at about $104, suggesting only a small gap to its implied worth.

Regardless of these risks in the near term, the present valuation for CVS indicates that the stock is considered undervalued by the street. At a P/E ratio of 10x, which is significantly lower than the sector average, CVS trades at a 71% discount to its peers and this points to potential upside if it is able to execute on its turnaround strategy. In H1 2024, revenue in the HCB segment increased by 23% YoY, indicating promising growth avenues. That perceived undervaluation of CVS, together with expected EPS growth in 2025, makes it a stock to watch closely as it works through the balance between costs and profitability for long-term investors.

The valuation story here depends on how fast earnings can rebuild, how far margins can recover, and how durable Health Care Benefits growth is. The narrative connects those moving pieces into one fair value view. If you want to see exactly which growth and profitability paths are incorporated into that $104 figure, the full breakdown is available.

Result: Fair Value of $104 (UNDERVALUED)

However, this depends on CVS containing medical cost pressures in Health Care Benefits and executing its US$2b restructuring without further charges or operational disruption.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Multiples Paint a Different Picture

Those fair value estimates around $104 suggest only a small undervaluation, but the current P/E of 44.4x tells a very different story. It sits well above both the peer average of 18.9x and a fair ratio of 37.6x, which points to a richer pricing multiple and less room for error.

For you as an investor, that gap means the market is already paying up for CVS Health’s earnings, so any setback in profit recovery could weigh more heavily on the stock than the DCF style narratives imply. Which lens do you trust more when the signals do not fully line up?

Next Steps

With sentiment mixed between upside potential and richer multiples, now is the moment to look at the data firsthand and pressure test your own thesis by weighing the 2 key rewards and 5 important warning signs.

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that could fit your goals even better, so keep widening your opportunity set thoughtfully.

• Target growth potential by scanning screener containing 20 high quality undiscovered gems that pair solid fundamentals with the chance to be noticed by the broader market later.
• Strengthen portfolio stability by reviewing solid balance sheet and fundamentals stocks screener (48 results) that focus on companies with resilient finances supporting their operations.
• Dial down overall portfolio risk by checking 71 resilient stocks with low risk scores built around businesses screened for lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.